


¹ Fatty Acid and Retinol-Binding Protein: Unusual Protein ² Conformational and Cavity Changes Dictated by Ligand ³ Fluctuations

⁴ G. P. Barletta,[†][‡] G. Franchini,[‡] B. Corsico,[‡] and S. Fernandez-Alberti^{*,†}[‡]

⁵ [†]Universidad Nacional de Quilmes/CONICET, Roque Saenz Peña 352, B1876BXD Bernal, Argentina

⁶ [‡]Instituto de Investigaciones Bioquímicas de La Plata, CONICET-UNLP, Facultad de Ciencias Médicas, calles 60 y 120 s/n, 1900 La Plata, Argentina

⁸  Supporting Information



ABSTRACT: Lipid-binding proteins (LBPs) are soluble proteins responsible for the uptake, transport, and storage of a large variety of hydrophobic lipophilic molecules including fatty acids, steroids, and other lipids in the cellular environment. Among the LBPs, fatty acid binding proteins (FABPs) present preferential binding affinities for long-chain fatty acids. While most of FABPs in vertebrates and invertebrates present similar β -barrel structures with ligands accommodated in their central cavity, parasitic nematode worms exhibit additional unusual α -helix rich fatty acid- and retinol-binding proteins (FAR). Herein, we report the comparison of extended molecular dynamics (MD) simulations performed on the ligand-free and palmitic acid-bond states of the *Necator americanus* FAR-1 (Na-FAR-1) with respect to other classical β -barrel FABPs. Principal component analysis (PCA) has been used to identify the different conformations adopted by each system during MD simulations. The α -helix fold encompasses a complex internal ligand-binding cavity with a remarkable conformational plasticity that allows reversible switching between distinct states in the holo-Na-FAR-1. The cavity can change up to one-third of its size affected by conformational changes of the protein–ligand complex. Besides, the ligand inside the cavity is not fixed but experiences large conformational changes between bent and stretched conformations. These changes in the ligand conformation follow changes in the cavity size dictated by the transient protein conformation. On the contrary, protein–ligand complex in β -barrel FABPs fluctuates around a unique conformation. The significantly more flexible holo-Na-FAR-1 ligand-cavity explains its larger ligand multiplicity respect to β -barrel FABPs.

1. INTRODUCTION

Hydrophobic lipophilic molecules like fatty acids, steroids, retinoids, and their derivatives participate in a large variety of functions within a cell, including energy storage, signaling, regulation of gene expression, hormonal roles, and membrane permeability regulation among others. Their insolubility in water and their potential oxidative degradation require their coordinated transport and availability, protection and regulation throughout the hydrophilic intracellular environment. Soluble lipid-binding proteins (LBPs) are a group of abundant proteins that are responsible for these tasks throughout the aqueous environment inside numerous types of cells¹ and body fluids of different organisms.² Helminth parasites have a restricted lipid metabolism and must acquire simple and complex lipids from their hosts,³ therefore LBPs probably

perform very important functions for parasite growth and development.

Fatty acid and retinol binding proteins (FARs) are LBPs that have been described as components of E/S fluids from parasitic nematodes^{4–7} and they are hypothesized to play essential roles in lipid acquisition and distribution of nutrients as well as potential dampening of host's immune response.^{8,9} FARs together with nematode polyprotein/allergens (NPAs)¹⁰ are small (14–20 kDa), helix rich proteins that bind retinol and fatty acids and have no recognizable counterparts in other animal groups.² Given these characteristics, FARs have been proven to be useful for serodiagnosis and experimental

Received: April 29, 2019

Published: July 31, 2019

50 vaccines.^{11–13} Moreover, there is evidence that FARs from 51 filarial nematodes are able to bind anthelmintic drugs.^{14,15}

52 Hookworm disease is a highly debilitating helminth infection 53 that is related to iron deficiency anemia (IDA) in tropical 54 developing countries with an estimated prevalence of 451 55 million cases that cause 1.6 million years lived with disability 56 (YLD).¹⁶ *Necator americanus*, together with *Ancylostoma* 57 *duodenale* and *Ancylostoma ceylanicum*, are the causative agents 58 for the above mention “hookworm disease”. It is important to 59 note that *N. americanus* is responsible for the majority of cases 60 worldwide. This parasitosis has been successfully eradicated 61 from developed countries by mass drug treatments and by 62 economic development.¹⁷ Nevertheless the levels of disease 63 burden remains high in many low middle income countries like 64 the north region of Argentina.¹⁸

65 FARs occur in several isoforms, and Na-FAR-1 has been 66 found to be highly expressed in the adult form.^{19,20} At the 67 present time, two orthologues FAR structures were solved, one 68 from *Necator americanus* (Na-FAR-1 by protein nuclear 69 magnetic resonance (NMR) and X-ray crystallography; PDB: 70 4UET and 4XCP, respectively)²⁰ and another from *Caeno-* 71 *rhabditis elegans* (Ce-FAR-7, by X-ray crystallography; PDB: 72 2W9Y).²¹ Both present similar overall α helix-rich structures 73 with certain structural differences. Particularly, the size and 74 shape of their internal cavities are different, denoting 75 differences in their ligand selectivity. Na-FAR-1, in either its 76 apo- and holo-conformations, presents a larger and more 77 complex internal ligand-binding cavity.²⁰

78 Among soluble LBPs, another interesting group is the fatty 79 acid binding proteins (FABPs) family presenting preferential 80 binding affinities for long-chain fatty acids.^{22–27} While FARs 81 have been found exclusively in nematodes²⁸ FABPs can be 82 found in vertebrates and invertebrates. Despite their low 83 sequence identity and their functional divergence, probably 84 related to their particular lipid-binding preferences, they share 85 a common tertiary structure.^{29,30} They all have similar β -barrel 86 structures that encase the bound fatty acid. The volume of the 87 inner ligand-binding cavity is determined by the side chains of 88 the residues that define the molecular surface enclosing it. 89 These residues vary between the different FABP types, and 90 they determine the ligand specificity of the cavity. Various 91 single point mutations, performed on residues lining the cavity 92 of different FABP types, have shown to modify the protein 93 conformational stability, ligand specificity and affinity.^{31–36} 94 Several studies, based on crystal and solution analysis, 95 predicted the way FAs enter and leave the FABP binding 96 site;^{24,37} this is fundamental to understanding the molecular 97 mechanism of ligand selection and delivery in FABPs.^{38,26,39–42} 98 These works have shown the importance of certain residues 99 and domains in the protein dynamics, confirming observations 100 performed by different experimental methods and allow to 101 hypothesize about these protein's proposed functions in the 102 cell. While nematodes also produce β -barrel FABPs, the 103 reasons why nematodes have specialized in the use of α -helix 104 rich proteins remain unclear.

105 An understanding of how the conformational diversity of 106 FARs contributes to their ligand multiplicity, varying the 107 relative affinities for different hydrophobic lipophilic mole- 108 cules, could enlighten their roles in parasitism and suggest 109 possible targets for therapeutic interventions. Fluorescence- 110 based ligand-binding assays and titration of Na-FAR-1 with 111 sodium oleate monitored by NMR reveal its high ligand 112 multiplicity.²⁰ These studies suggest the higher propensity of

113 the α -helical fold to bind a larger variety and quantity of FAs 114 and other lipid classes than the β -barrel fold. Besides, Na-FAR- 115 1 ligand-binding induces substantial chemical shift changes for 116 residues throughout the protein, indicating significant con- 117formational changes that allow the structure to expand.¹¹⁷

118 Molecular dynamics (MD) simulations^{43–46} combined with 119 principal component analysis (PCA)^{47–51} provide a framework 120 for decomposing the complexity of proteins motions into 121 decoupled individual contributions. PCA is a useful multi- 122 variate statistical method that has been applied to reduce the 123 number of dimensions needed to describe protein dynamics.¹²³ This combination of MD and PCA has recently been applied 124 to develop a procedure that reveals the existence of 125 correlations between the dynamics of cavities and struc- 126 tures.^{52,53} Besides, MD simulations have shown to be the 127 adequate computation method to reveal several dynamic and 128 functional aspects of LBPs,^{54,55,40,56} like ligand entry and leave 129 pathways and complex formation,^{26,39,57} and binding-relevant 130 intermediate states.⁴² Moreover, MD simulation of the 131 flexibility of the internal cavity has shown to be a requirement 132 for a good simulation of ligand-LBPs affinities.⁵⁸

133 Herein we explore the structure-dynamics-function relation- 134 ship of Na-FAR-1 using long molecular dynamics simulations 135 combined with PCA in its *apo*- and *holo*-forms. We analyze its 136 plasticity and the impact of the different conformations on the 137 ligand-binding cavity volume. We were focused on the 138 dynamics relationships between protein fluctuations, cavity 139 changes, and the enclosed ligand different conformations. A 140 comparison of our results with those obtained from MD 141 simulations of the rat intestinal fatty-acid-binding protein (I- 142 FABP) with the typical FABP β -barrel fold, and the orthologue 143 Ce-FAR-7 is performed. Our analysis reveals that Na-FAR-1 144 encompasses a complex internal ligand-binding cavity with a 145 remarkable conformational plasticity that allows reversible 146 switching between distinct states according with the enclosed 147 ligand different conformations.¹⁴⁸

2. METHODS

149 **2.1. Molecular Dynamics simulations.** Molecular 150 dynamics (MD) simulations were performed for Na-FAR-1 151 and I-FABP, both in their *apo*- and *holo*- forms with palmitate 152 in their binding pockets, and Ce-FAR-7 in its unligated form.^{59,60} 153 These were carried out with AMBER 16 software package.¹⁵³ 154 Initial structures for each protein were obtained from the 155 protein data bank⁶¹ (pdb id 4UET (no. of atoms = 23173) and 155 4XCP (no. of atoms = 22707) for *apo*- and *holo*-Na-FAR-1²⁰ 156 respectively, 1IFB⁶² (no. of atoms = 15502) for *apo*-I-FABP,¹⁵⁷ 2IFB⁶³ (no. of atoms = 15768) and 1URE⁶⁴ (no. of atoms = 158 16143) for *holo*-I-FABPs and 2W9Y²¹ (no. of atoms 21528) 159 for *apo*- Ce-FAR-7). Each protein was solvated with explicit 160 water molecules in a rectangular periodic box large enough to 161 contain the protein and 10 Å of solvent on all sides. Ions are 162 added for charge neutralization. Periodic boundary conditions 163 and particle-mesh Ewald (PME) sums were applied. The 164 AMBER ff14SB^{65,66} force field and the TIP3P⁶⁷ water model 165 were used in all simulations. Minimization of each system was 166 performed in two steps: first, constraints were applied to the 167 protein atoms and 200-steps of steepest-descent and 800-steps 168 of conjugate gradient minimization were run; then, constraints 169 are lifted and the same procedure were applied again. This was 170 followed by 400 ps of heating to reach the final temperature of 171 300 K. During heating a harmonic constraint of 25.0 (kcal/ 172 mol)/Å² was applied to the protein atoms. The time step was 2 173




Figure 1. Averaged (b) *apo*- and (d) *holo*-structures for Na-FAR-1 obtained from the corresponding equilibrated MD simulations, indicating the main secondary structure elements (SSE) and the encompassed ligand cavity. Distribution of ligand cavity volumes, calculated over the set of structures collected during the equilibrated MD simulations of (a) *apo*- and (c) *holo*-Na-FAR-1.

174 fs, and the SHAKE algorithm was employed to constrain bonds
 175 involving hydrogen atoms. A cutoff of 10 Å was applied to
 176 nonbonded interactions. Systems were equilibrated for 7.8 ns
 177 at constant pressure gradually reducing the constraints every
 178 100 ps until all restraints were lifted. After that, the systems
 179 were equilibrated at the constant temperature of 300 K using
 180 the Andersen barostat and the Langevin thermostat with a γ
 181 collision frequency of 2 ps⁻¹ during 12.2 ns. Finally, 3- μ s
 182 production MD runs were performed, during which config-
 183 urations were collected at 10 ps intervals.

184 **2.2. Principal Component Analysis.** PCA is an
 185 extensively used statistical procedure to identify the essential
 186 dynamics from MD simulations^{47–51,68} and, thereby, facilitate
 187 the study of long time dynamics. For the sake of consistency,
 188 we briefly review PCA below.

189 Herein, PCA modes \mathbf{Q}_i are $3N$ orthogonal eigenvectors
 190 obtained as columns of the eigenvector matrix \mathbf{L} , that results
 191 after diagonalizing ($\mathbf{L}^T \mathbf{C} \mathbf{L} = \Lambda$) the covariance matrix of
 192 atomic fluctuations \mathbf{C} whose elements are defined as

$$C_{ij} = \langle q_i q_j \rangle = \frac{1}{K} \sum_{k=1}^K q_i^k q_j^k \quad (1)$$

193 where the sum goes over the K configurations stored during
 194 previously equilibrated MD simulations, $q_i^k = \sqrt{m_i} (x_i^k - \langle x_i \rangle)$
 195 is the mass-weighted internal displacement of Cartesian
 196 coordinate x_i^k of the i th atom ($i = 1, \dots, N$; N = number of
 197 residues in the protein (C_α) with mass m_i , and the angular
 198 brackets represent the average obtained from the K
 199 configurations.⁶⁸ The elements of the diagonal matrix Λ
 200 represent the relative contribution of each PCA or essential
 201 mode (EM) to the overall fluctuation of the molecule. The
 202 eigenvectors are typically ordered according to descending
 203 eigenvalues, with the first PCA mode being the one with major
 204 contribution.

205 **2.3. Ligand-Cavities: Definition, Volume, and Flexi-
 206 bility.** Ligand-cavities have been defined by visual inspection
 207 of the average of equilibrated MD structures and previous

knowledge on each system. The complete list of residues lining
 209 the main ligand-binding cavity for each system is provided in
 210 the *Supporting Information* (Table S1).

211 Cavity volumes are calculated using our previously
 212 developed method,⁵³ particularly suited to measure changes
 213 in cavity volumes due to small atomic coordinate displace-
 214 ments in the direction of specific predefined directions of
 215 protein structural displacements. Following our previous works
 216 we make use of the volume gradient vector (∇V_{ol}), defined as
 217 the vector of partial derivatives of the cavity volume in the
 218 basis of PCA modes $\{\mathbf{Q}_i\}_{i=1,3N}$, that is

$$\nabla V_{ol} = \sum_{i=1}^{3N} c_i \mathbf{Q}_i = \sum_{i=1}^{3N} \frac{\partial V_{ol}}{\partial Q_i} \mathbf{Q}_i \quad (2)$$

219 Within the frame of the quasi-harmonic analysis approx-
 220 imation,⁶⁹ the variation of the potential energy of a protein in
 221 the direction of ∇V_{ol} is defined as

$$\nabla E_{\nabla V_{ol}} = \sum_{i=1}^{3N} \Delta E_{\mathbf{Q}_i} \quad (3)$$

222 with

$$\Delta E_{\mathbf{Q}_i} = \frac{1}{2} k_i \epsilon_i^2 \Delta X^2 \quad (4)$$

223 being $k_i = \frac{k_B T}{\lambda_i}$, k_B the Boltzmann constant and T the absolute
 224 temperature (300 K). ΔX represents a relative displacement in
 225 the direction of ∇V_{ol} . Therefore, we consider $\Delta E_{\nabla V_{ol}}$ as
 226 a measure of flexibility of the cavities.

3. RESULTS AND DISCUSSION

227 **3.1. α -Helix Rich FARs.** While most of FABPs present a β -
 228 barrel folding, FARs reveals an unusual α -helical fold. In the
 229 case of Na-FAR-1, it consists of a wedge-shaped structure
 230 composed of 11 helices with different lengths that enclose an
 231 internal ligand-binding cavity. The overall ligand-binding
 232 conformational change involve a global RMSD of 0.98 Å

237 between conformers, calculated from the α -carbons super-
 238 position of averaged *apo*- and *holo*-structures obtained from the
 239 corresponding equilibrated MD simulations (see Figure 1b,d).
 240 Both *holo*-states for Na-FAR-1 and I-FABP are bound to a
 241 single molecule of palmitate. It is important to note that this is
 242 the preferred ligand of Na-FAR-1 in a biological environment.²⁰
 243 The main structural distortions upon ligand binding are
 244 localized on helices α_{10} , α_2 , α_7 , α_{10} and the loops between α_1 –
 245 α_2 , α_2 – α_3 , α_4 – α_5 , and α_7 – α_8 . Among these Secondary
 246 Structure Elements (SSE), α_4 – α_5 and α_7 – α_8 have shown the
 247 largest root-mean-square fluctuations (RMSF; see Figure S1)
 248 during our MD simulations, particularly residues 39–45 in α_4 –
 249 α_5 loop and residues 100–103 in α_7 – α_8 loop present the
 250 largest relative flexibility. The structural change of α_4 – α_5 loop
 251 during ligand-binding is expected since this loop is part of the
 252 single opening of the ligand-binding cavity, located between
 253 this loop and helices α_6 and α_7 . Besides this opening, α_7 – α_8
 254 loop has been previously proposed²⁰ as the main candidate to
 255 participate of the ligand entrance through the portion of the
 256 cavity accessible to solvent.

257 At this point it is interesting to note that the RMSD between
 258 average *holo*- and *apo*- structures of Na-FAR-1 is only 1.58 Å.
 259 Nevertheless, in a previous article,⁷⁰ we have pointed out that
 260 small structural distortions can involve large changes in the
 261 cavities of the proteins. Besides, in cases that proteins explore
 262 multiple conformers during MD simulations, the average
 263 structural is not a good statistics. Therefore, in what follows,
 264 the identification of different conformers and their impact on
 265 the ligand-cavity is discussed.

266 A further inspection of the internal ligand-binding cavity can
 267 be seen in Figure 1a,c where the distributions of cavity
 268 volumes, calculated over the set of structures collected during
 269 the equilibrated MD simulations of *apo*- and *holo*-Na-FAR-1,
 270 are shown. Their average values are 1353 ± 254 and $1397 \pm$
 271 266 \AA^3 respectively. These values differ from the corresponding
 272 940 and 2170 \AA^3 calculated on the initial experimental
 273 structures.²⁰ As we have pointed out previously, we define
 274 internal cavities according to average structures obtained from
 275 our MD simulations. The distributions shown in Figure 1a,c
 276 are the result of the protein thermal fluctuations that can
 277 involve different conformational changes throughout the 3- μ s
 278 of MD simulations. Fluctuations of helices that form the cavity
 279 introduce relatively small protein structural rearrangements
 280 that can lead to significant changes on the internal cavity size.⁷⁰
 281 Histograms shown in Figure 1a,c reveal that internal cavity can
 282 duplicate its volume due to protein fluctuations. While the
 283 distribution of volume cavities for *apo*-Na-FAR-1 corresponds
 284 to a Gaussian distribution that can be associated with thermal
 285 fluctuations around a unique protein conformation, this is not
 286 the case for *holo*-Na-FAR-1.

287 Volume cavity changes can be associated with protein
 288 fluctuations. Therefore, in order to elucidate this feature, MD
 289 simulations were analyzed in terms of PCA. The first and
 290 second PCA modes of *apo*- and *holo*-Na-FAR-1 are shown in
 291 Figure 2a,b. In both conformers, the first 2 modes involve the
 292 concerted motion of residues located in helices α_4 , α_5 , the
 293 loop between, and the C-term of the helix α_7 . In agreement
 294 with previous experimental observations,²⁰ the last helix has
 295 the most impact on cavity volume, while the former form the
 296 ligand entrance gate (α_4 – α_5 gate).

297 Figure 3a,b show the projection of the set of MD snapshots
 298 of *apo*- and *holo*-Na-FAR-1 onto their corresponding first and
 299 second PCA modes. Thermal fluctuations of *apo*-Na-FAR-1 are




Figure 2. 1st (red) and 2nd (blue) PCA modes of (a) *apo*- and (b) *holo*-Na-FAR-1.




Figure 3. Contour density plots of the projection of the set of MD snapshots of (a) *apo*- and (b) *holo*-Na-FAR-1 onto their corresponding 1st and 2nd PCA modes.

revealed as gradual combinations of both modes without showing significant prevalence of structural distortions in any specific direction. That is, *apo*-Na-FAR-1 does not visit any new conformation that persists a significant amount of time during the MD simulation. On the contrary, we can observe that *holo*-Na-FAR-1 actually evidence the existence of three different conformers: two stable conformers presenting structural distortions mainly in both senses of the direction of the first PCA mode (conformers A and B), and a third conformer C in the direction of the second PCA mode. The projections of the set of MD snapshots of *apo*- and *holo*-Na-FAR-1 onto their corresponding third PCA modes do not show the existence of new stable conformers with structural distortions in the direction of these modes (see Figure S2). The major differences among conformers A, B, and C lie in the α_4 – α_5 gate and the helix α_7 . Conformer A's α_7 helix is relatively straightened, allowing the α_4 – α_5 gate to close up. B's α_7 helix has a kink next to its C-term around ILE 104, which displaces the α_4 – α_5 gate. This kink is even steeper in Conformer C. This kink is the main reason for the volume decrease in conformers B and C (see Figure 4a). Therefore, the distribution of internal cavity volumes shown in Figure 1c can be interpreted as the contribution of three different conformations explored by *holo*-Na-FAR-1 during the MD




Figure 4. (a) Superposition of the three conformers (A, B, and C) of holo-Na-FAR-1; (b) distribution of cavity volumes for each of the conformers (A, B, and C) of holo-Na-FAR-1 during the MD simulation; (c) evolution in time of the cavity volume displaying the different contributions of each of the three A, B, and C conformers.

324 simulation. Figure 4b shows the distribution of cavity volumes 325 for each of them. While two of the *holo*-Na-FAR-1 conformers 326 (B and C) enclose relative small internal cavities with average 327 volumes of 1130 ± 126 and 1211 ± 150 Å³, the other 328 conformer (A) presents a large cavity of 1568 ± 222 Å³. These 329 results indicate that *holo*-Na-FAR-1 presents a remarkable 330 conformational plasticity that drives a complex internal cavity 331 dynamics. The three identified conformers are in dynamical 332 equilibrium connected by conformational changes involving 333 the first and the second PCA modes. Figure 4c shows the 334 evolution in time of the cavity volume displaying the different 335 contributions of each of the three conformers. Reversible 336 interconversions between them can be observed during the 337 MD simulation. These results are in complete agreement with 338 our previous analysis of the *apo* and *holo* structures of Na-FAR- 339 1 employing NMR spectroscopy.²⁰ In the referred work, NMR 340 spectra of *holo*-Na-FAR-1 in solution, like those of other FAR 341 proteins previously tested, were characterized by broad signal 342 peaks indicative of multiple conformations and/or conforma- 343 tional exchange. However, *apo*-Na-FAR-1 gave good solution 344 NMR spectra which allowed the structure of *apo*-Na-FAR-1 to 345 be determined. In the same work the ligand binding process 346 was followed through NMR and showed that the protein 347 exhibited slow exchange behavior through the addition of 1, 2, 348 and 3 mol equiv of the ligand (oleate), which would suggest 349 that the protein binds three ligands with high affinity. The 350 higher plasticity of the protein after the incorporation of one 351 molecule of ligand, as shown in the present work, would

eventually make the protein more susceptible to accept more 352 ligand molecules. 353

In order to further understand the effect of higher 354 conformational plasticity of *holo*-Na-FAR-1 respect to *apo*- 355 Na-FAR-1 on the ligand binding, the dynamics of the ligand 356 within the cavity has been explored. For this purpose, ligand 357 structural fluctuations have been analyzed using PCA. Figure 358 fs 5(a) shows the projection of the ligand structures, obtained 359 fs




Figure 5. (a) Contour density plots of the projection of the palmitate structures, obtained from the set of MD snapshots of *holo*-Na-FAR-1, onto its 1st and 2nd PCA modes; (b) distribution of cavity volumes according to the conformation of the ligand encompassed in it; (c) evolution in time of the cavity volume displaying the different conformations adopted by the ligand.

throughout the MD simulation, onto its first and second PCA 360 modes. Two distinctive ligand conformations represented by 361 the structural distortions in both senses of the direction of the 362 first PCA mode can be observed. They correspond to the bent 363 and stretched conformations shown in Figure 5a. As can be 364 seen in Figure 5b, the ligand fluctuates between them, being 365 the stretched conformation associated with large cavity 366 volumes while the bent one is observed within smaller cavity 367 volumes (Figure 5c). That is, far from being fixed within the 368 cavity, the ligand experiences large conformational changes 369 associated with changes of cavity volume. 370

The relationship between the different *holo*-Na-FAR-1 371 conformers, with their corresponding associated changes in 372 the internal cavity volume, and the different ligand 373 conformations can be analyzed by depicting the distribution 374 of distances between the extremes of the palmitate molecule, 375 that is, the distance from the C atom of carboxyl group to the 376 C atom of the methyl group (see Figure 6). We can observe 377 fs that the stretched palmitate conformation is associated with 378 the *holo*-Na-FAR-1 conformer (A) with the largest internal 379 cavity and the straightened α 7 helix to make room for the 380




Figure 6. Distribution of distances between the extremes of the palmitate molecule for each of the conformers (A, B, and C) of *holo*-Na-FAR-1 during the MD simulation.

381 ligand, while the bent conformation is mainly present on the
 382 other two conformers (B and C). Since the three *holo*-Na-
 383 FAR-1 conformers are in dynamics equilibrium during the MD
 384 simulation (see Figure 4c), the ligand changes its conformation
 385 accordingly to the corresponding changes in the cavity sizes
 386 associated with each protein conformational change.

387 Finally, MD simulations have been performed on the
 388 orthologue Ce-FAR-7 in its *apo*-conformation. Figure 7b
 389 shows the average structure obtained from the corresponding
 390 equilibrated MD simulation. Ce-FAR-7 is an orthologue of Na-
 391 FAR-1 that, despite its similar overall fold, it presents an
 392 internal cavity different in size and shape respect to Na-FAR-
 393 1.²⁰ Therefore, a comparison of the relative flexibility of the
 394 ligand-binding cavities for Ce-FAR-7 and Na-FAR-1 can
 395 enlighten on the origin of the differences in their ligand
 396 binding and biological properties.

397 The RMSD between average *apo*-Na-FAR-1 and *apo*-Ce-
 398 FAR-7 is 2.77 Å. In agreement with *apo*-Na-FAR-1, Figure 7a
 399 shows that the distribution of its internal cavity volume can be
 400 associated with protein fluctuations around a unique
 401 conformation characterized by a free energy landscape with a
 402 relatively deep well. These results are in agreement with the
 403 observations made by Rey-Burusco et al.²⁰ where the estimated
 404 cavity for Ce-FAR-7 calculated revealed a much smaller size
 405 than for both forms of Na-FAR-1.

406 **3.2. β -Barrel FABPs.** While FARs exhibit α -helix rich folds,
 407 most FABPs present a typical FABP β -barrel fold that includes
 408 a small and displaced hydrophobic core and a cavity filled with
 409 water molecules. In order to understand how the different folds
 410 impact on the protein properties associated with the transport
 411 of a variety of ligands with different shapes and sizes, MD
 412 simulations have been performed on the rat intestinal fatty-
 413 acid-binding protein (I-FABP) in its *holo* and *apo* forms. The
 414 ligand-binding conformational change involves a structural

distortion with a RMSD = 1.00 Å. The average internal ligand- 415 cavity is significantly smaller than Na-FAR-1, being 605 ± 145 416 and 926 ± 85 Å³ for *apo*-I-FABP and *holo* I-FABP respectively 417 (see Figure 8). We can observe that the distribution of cavity 418 volumes for *apo*-I-FABP can be associated with the 419 contribution of different conformations explored during the 420 MD simulation. On the contrary, ligand-binding funnels *holo*-I- 421 FABP onto a unique rigid state. These results are in good 422 agreement with previous NMR measurements performed on 423 human L-FABP⁷¹ and rat I-FABP⁷² that describe ligand 424 binding as a transition of the protein structure from a slightly 425 more disordered and flexible *apo*-state to a more ordered *holo*- 426 state. Additionally, limited proteolysis experiments performed 427 on apo- and holo- rat IFABP showed that the holo-form was 428 resistant to overnight treatment while apo-IFABP was fully 429 degraded.^{73,74} This analysis have also been applied on cestodes 430 FABPs yielding the same result.⁷⁵ Besides, the comparison of 431 RMSF obtained during our MD simulations indicates larger 432 fluctuations for the *apo*- than for the *holo*- I-FABP (see Figure 433 S1). This is in good agreement with the results of Matsuoka et 434 al.⁴⁰ where the authors show that the calculated RMSF values 435 were less than 1.0 Å for almost all protein residues, indicating 436 that this protein is rigid in the ligand-bound form. This 437 increased mobility and discrete disorder in the *apo*-state may 438 facilitate the entry of the ligand into the cavity. 439

PCA allows the identification of the different *apo*-I-FABP 440 conformers and their corresponding effect on the volume of 441 the internal cavity (see Figure 9a,b). Four different conformers, 442 f9 associated with different combinations of structural distortions 443 in the directions of the first and second PCA modes, have been 444 identified (see also Figure S3 and Figure S4). Two of them (A 445 and B) are associated with smaller cavity volumes than the 446 other two(C and D). Figures 9c shows that *apo*-I-FABP 447 experiences multiple conformational changes throughout the 448 MD simulation, indicating a relatively low energy barrier 449 between its states. On the contrary, the projection of the set of 450 MD snapshots of *holo*-I-FABP onto its first and second PCA 451 modes does not reveal the existence of multiple conformers 452 but rather a unique rigid state (see Figure S5). This is in 453 agreement with the distribution of its cavity volumes, shown in 454 Figure 8c, represented as a Gaussian distribution that can be 455 associated with fluctuations around a unique minimum in the 456 protein conformational space. Ligand binding seems to shift 457 the conformational equilibrium of I-FABP to a unique 458 conformation with a sufficiently deep well to ensure that a 459 significant fraction of protein molecules are trapped fluctuating 460 in it. 461

3.3. Relative Flexibility of the Ligand-Cavities. The 462 different FARs and FABPs analyzed in this study have shown 463





Figure 7. (a) Distribution of its internal cavity volume, calculated over the set of collected MD structures. (b) Averaged structure of *apo*-Ce-FAR-7 obtained from the equilibrated MD simulation.




Figure 8. Distribution of ligand cavity volumes, calculated over the set of structures collected during the equilibrated MD simulations of (a) *apo*- and (c) *holo*- I-FABP. Averaged (b) *apo*- and (d) *holo*-structures for I-FABP obtained from the corresponding equilibrated MD simulations, indicating the main secondary structure elements (SSE) and the encompass ligand cavity.

464 ligand-cavities with different shapes whose dynamics is subject
 465 to the corresponding protein plasticity. In order to analyze
 466 which LBP fold encompasses a more flexible cavity and,
 467 therefore, a cavity that can contribute to a larger ligand
 468 multiplicity, we calculated the variation of the potential energy
 469 of each LBP in the direction of ∇V_o (see section 2.3). Results
 470 are shown in Figure 10a. We consider the amplitude of the
 471 displacement in the direction of ∇V_o achieved with an energy
 472 equal to $kT = 0.593$ kcal/mol (with k being the Boltzmann's
 473 constant and $T = 298$ K) as a measure of flexibility of the
 474 cavity.⁵³ We can observe that the internal cavity of *apo*-I-FABP
 475 results the most flexible one, followed by *holo*- and *apo*-Na-
 476 FAR-1. *Apo*-Ce-FAR-7 presents a relatively more rigid cavity.
 477 Besides, the two *holo*-I-FABPs (1URE and 2IFB) enclose the
 478 most rigid cavities, reinforcing the idea that β -barrel I-FABPs
 479 follow a ligand-binding strategy involving a *holo*-state with
 480 restricted motional freedom.

481 While both *holo*-Na-FAR-1 and *apo*-I-FABP encompass
 482 cavities with different sizes according to the transient protein
 483 conformation, Figure 10b,c displays the analysis of the
 484 corresponding individual conformers. We can observe that,
 485 in both cases, each conformer result relatively more rigid than
 486 the average shown in Figure 10a, indicating that their
 487 individual contributions introduce an additional component
 488 to the overall flexibility of the cavity. Furthermore, *holo*-Na-
 489 FAR-1 conformers are less rigid than the average (see Figure
 490 10b) compared to *apo*-I-FABP conformers relative to their
 491 corresponding average (see Figure 10c). That is, the flexibility
 492 of *holo*-Na-FAR-1 seems to be more uniformly distributed
 493 among the conformer populations in dynamic equilibrium.
 494 Therefore, we conclude that the native state of I-FABP, defined
 495 as an equilibrium of pre-existing populations of states, can be
 496 considered in general more flexible than the native state of I-
 497 FABP. These results indicate a propensity of Na-FAR-1 to bind
 498 not only fatty acids but also a broader range of lipid classes
 499 such as retinol and phospholipids. This feature is in agreement
 500 with previous fluorescence experiments performed on Na-
 501 FAR-1 and Ce-FAR-7.²⁰

4. CONCLUSIONS

Parasitic helminths produce and release an unexpectedly wide range of LBPs that are structurally distinct from those of their hosts. Although poorly understood, helminth LBPs are often immunodominant in infection. Some of them attract allergic-type antibody responses and have been associated with protective immunity.^{4,76–78} The evolutionary reasons why a single species expresses different types of LBPs remain unclear. FARs are commonly found in the secretions of parasitic nematodes, possibly indicating their role in parasitism. Parasites need to acquire nutrients from their hosts and they also need to defend themselves against immune response from the host. In this sense, it is hypothesized that they interfere by sequestering signaling lipids produced by the host. Therefore, a large ligand multiplicity of FARs would help in both lipid acquisition and sequestering. As mentioned before they have also been proven as good vaccine candidates.¹³

Protein fluctuations—cavity changes relationships have been explored on different α -helix rich FARs and β -barrel FABPs using long equilibrated MD simulations of either *apo*- and *holo*- states. We found a significantly flexible Na-FAR-1 ligand-cavity that can explain the observed larger ligand multiplicity of α -helix FARs respect to β -barrel FABPs. The comparison of the relative flexibility of ligand-binding cavities of Ce-FAR-7 and Na-FAR-1 reveals how a similar fold can enclose internal cavities with significant differences in their flexibilities and dynamics. These differences can explain differences in their ligand multiplicity and, therefore, their biological function. Moreover, differences in ligand binding capacities have been observed between two isoforms from the same species.¹³

We have reported two different ligand-binding strategies. Particularly, *holo*-Na-FAR-1 presents a remarkable conformational plasticity that drives a complex internal cavity dynamics involving different states. The size of the cavity is significantly affected by protein conformational changes. Besides, the ligand also changes its conformation according to these conformational changes. That is, far from being fixed within the cavity,




Figure 9. (a) Contour density plots of the projection of the set of MD snapshots of *apo*-I-FABP onto its 1st and 2nd PCA modes; (b) distribution of cavity volumes for each of the *apo*-I-FABP conformers (A, B, C, and D) during the MD simulation; (c) evolution in time of the cavity volume displaying the different contributions of each of the four conformers A, B, C, and D conformers.

538 the ligand experiences large conformational changes between a
 539 bent and stretch conformation. The ligand conformation
 540 changes according to the size of the cavity that is dictated by
 541 the transient protein conformation. On the contrary, ligand
 542 binding in I-FABPs seems to shift the conformational
 543 equilibrium to a unique conformation. In this way, α -helix
 544 FARs and β -barrel FABPs seem to follow two different
 545 strategies for ligand-binding. FARs involve a *holo*-state with
 546 high plasticity; they experience conformational changes that
 547 significantly impact on the cavity volume and embedded ligand
 548 conformations. On the other hand, FABPs experience an
 549 inverse ligand-modulated disorder–order transition leading to
 550 a *holo*-state with restricted motional freedom. This piece of
 551 information could give light on the biological reasons for the
 552 existence of different LBPs types in the same organism.
 553 Human hookworm infections represent a significant
 554 problem in South America. There is an urgent need to design
 555 new treatments based on the knowledge of the metabolism of
 556 the parasites. Na-FAR1 has shown to be part of the excretion/
 557 secretion products, playing an important role in the host-
 558 parasite relationship. It may participate in the acquisition of
 559 lipids from the host or sequestering signaling molecules
 560 dampening the immune response from the host. The detailed
 561 knowledge of the structural and dynamics properties of its




Figure 10. Potential energy change in the direction of ∇V_{ol} for each (a) protein structure, (b) *holo*-Na-FAR-1 conformer, and (c) *apo*-I-FABP conformer. The black line indicated as $kT = 0.593 \text{ kcal/mol}$ (with k being the Boltzmann's constant and $T = 298 \text{ K}$) has been added as reference of the average energy per degree of freedom at room temperature.

ligand-binding cavity could contribute to the design of new and 562 more specific inhibitors. The flexibility of protein cavities 563 impacts on functional aspects like ligand affinities and binding 564 promiscuities. The present work can encourage the develop- 565 ment of drugs that rigidize the cavity of Na-FAR-1, reducing its 566 ligand multiplicity and, therefore, the efficiency to play its 567 biological function. 568

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the 571 ACS Publications website at DOI: 10.1021/acs.jcim.9b00364. 572

Table S1: List of residues lining the main ligand-binding 573 cavity for each system. Residues are numbered according 574 to their order in the corresponded PDB file. Figure S1: 575 Root mean square fluctuations (RMSF) during our MD 576 simulations. Figure S2: Histogram of the projection of 577 the set of MD snapshots of holo-I-FABP onto its third 578 PCA mode. Figure S3: First (red) and second (blue) 579 PCA modes of (a) apo- and (b) holo-I-FABP. Figure S4: 580 Superposition of the four conformers (A, B, C, and D) 581 of apo-I-FABP. Figure S5: Contour density plots of the 582 projection of the set of MD snapshots of holo-I-FABP 583 onto their corresponding first and second PCA modes 584 (PDF) 585

586 ■ AUTHOR INFORMATION

587 Corresponding Author

588 *E-mail: sfalberti@gmail.com.

589 ORCID

590 G. P. Barletta: 0000-0002-0806-0812

591 S. Fernandez-Alberti: 0000-0002-0916-5069

592 Notes

593 The authors declare no competing financial interest.

594 ■ REFERENCES

- 595 (1) Lucke, C.; Gutierrez-Gonzales, L. H.; Hamilton, J. Intracellular
596 Lipid Binding Proteins: Evolution, Structure, and Ligand Binding. In
597 *Cellular proteins and their ligand fatty acids—emerging roles in gene
598 expression, health and disease*; Duttaroy, A., Spener, F., Eds.; Wiley:
599 New York, 2003; pp 95–114.
- 600 (2) Franchini, G.; Pórfigo, J.; Ibáñez Shimabukuro, M.; Rey Burusco,
601 M.; Bélamo, J.; Smith, B.; Kennedy, M.; Córscico, B. The Unusual
602 Lipid-Binding Proteins of Parasitic Helminths and Their Potential
603 Roles in Parasitism and as Therapeutic Targets. *Prostaglandins
604 Leukotrienes Essent. Fatty Acids* **2015**, *93*, 31–36.
- 605 (3) Barrett, J. Forty Years of Helminth Biochemistry. *Parasitology*
606 **2009**, *136* (12), 1633–1642.
- 607 (4) Mei, B.; Kennedy, M. W.; Beauchamp, J.; Komuniecki, P. R.;
608 Komuniecki, R. Secretion of a Novel, Developmentally Regulated
609 Fatty Acid-Binding Protein into the Perivitelline Fluid of the Parasitic
610 Nematode *Ascaris Stuum. J. Biol. Chem.* **1997**, *272*, 9933–9941.
- 611 (5) Plenefisch, J.; Xiao, H.; Mei, B. S.; Geng, J. M.; Komuniecki, P.
612 R.; Komuniecki, R. Secretion of a Novel Class of IFABPs in
613 Nematodes: Coordinate Use of the *Ascaris/Caenorhabditis* Model
614 Systems. *Mol. Biochem. Parasitol.* **2000**, *105*, 223–236.
- 615 (6) Garofalo, A.; Rowlinson, M. C.; Amambua, N. A.; Hughes, J. M.;
616 Kelly, S. M.; Price, N. C.; Cooper, A.; Watson, D. G.; Kennedy, M.
617 W.; Bradley, J. E. The FAR Protein Family of the Nematode
618 *Caenorhabditis Elegans* - Differential Lipid Binding Properties,
619 Structural Characteristics, and Developmental Regulation. *J. Biol.
620 Chem.* **2003**, *278*, 8065–8074.
- 621 (7) Jones, J. T.; Kumar, A.; Pylypenko, L. A.;
622 Thirugnanasambandam, A.; Castelli, L.; Chapman, S.; Cock, P. J.;
623 Grenier, E.; Lilley, C. J.; Phillips, M. S.; Blok, V. C. Identification and
624 Functional Characterization of Effectors in Expressed Sequence Tags
625 from Various Life Cycle Stages of the Potato Cyst Nematode
626 *Globodera Pallida. Mol. Plant Pathol.* **2009**, *10*, 815–828.
- 627 (8) Kennedy, M. W.; Garside, L. H.; Goodrick, L. E.; McDermott,
628 L.; Brass, A.; Price, N. C.; Kelly, S. M.; Cooper, A.; Bradley, J. E. The
629 Ov20 Protein of the Parasitic Nematode *Onchocerca Volvulus* - a
630 Structurally Novel Class of Small Helix-Rich Retinol-Binding
631 Proteins. *J. Biol. Chem.* **1997**, *272*, 29442–29448.
- 632 (9) Iberkleid, I.; Vieira, P.; de Almeida Engler, J.; Firester, K.;
633 Spiegel, Y.; Horowitz, S. B. Fatty Acid-and Retinol-Binding Protein,
634 Mj-FAR-1 Induces Tomato Host Susceptibility to Root-Knot
635 Nematodes. *PLoS One* **2013**, *8*, e64586.
- 636 (10) Solovyova, A.; Meenan, N.; McDermott, L.; Garofalo, A.;
637 Bradley, J.; Kennedy, M.; Byron, O. The Polyprotein and FAR Lipid
638 Binding Proteins of Nematodes: Shape and Monomer/Dimer States
639 in Ligand-Free and Bound Forms. *Eur. Biophys. J.* **2003**, *32* (5), 465–
640 476.
- 641 (11) Fairfax, K. C.; Vermeire, J. J.; Harrison, L. M.; Bungiro, R. D.;
642 Grant, W.; Husain, S. Z.; Cappello, M. Characterisation of a Fatty
643 Acid and Retinol Binding Protein Orthologue from the Hookworm
644 *Ancylostoma Ceylanicum. Int. J. Parasitol.* **2009**, *39*, 1561–1571.
- 645 (12) Burbelo, P. D.; Leahy, H. P.; Iadarola, M. J.; Nutman, T. B. A
646 Four-Antigen Mixture for Rapid Assessment of *Onchocerca Volvulus*
647 Infection. *PLoS Neglected Trop. Dis.* **2009**, *3*, e438.
- 648 (13) Zhan, B.; Arumugam, S.; Kennedy, M.; Tricoche, N.; Lian, L.-
649 Y.; Asojo, O.; Bennuru, S.; Bottazzi, M.; Hotez, P. J.; Lustigman, S.;
650 Klei, T. R. Ligand Binding Properties of Two *Brugia Malayi* Fatty
651 Acid and Retinol (FAR) Binding Proteins and Their Vaccine
652 Efficacies against Challenge Infection in Gerbils. *PLoS Neglected
Trop. Dis.* **2018**, *12* (10), e0006772.
- 653 (14) Lal, P. G.; James, E. R. Onchocerca Retinol- and Ivermectin-
654 Binding Protein Activity. *Parasitology* **1996**, *112* (2), 221–225.
- 655 (15) Sani, B.; Vaid, A. Specific Interaction of Ivermectin with
656 Retinol-Binding Protein from Filarial Parasites. *Biochem. J.* **1988**, *249*, 657
929–932.
- 658 (16) Vos, T.; et al. Global, Regional, and National Incidence,
659 Prevalence, and Years Lived with Disability for 328 Diseases and
660 Injuries for 195 Countries, 1990–2016: A Systematic Analysis for the
661 Global Burden of Disease Study. *Lancet* **2017**, *390* (10100), 1211–
662 1259.
- 663 (17) Loukas, A.; Hotez, P.; Diemert, D.; Yazdanbakhsh, M.;
664 McCarthy, J.; Correa-Oliveira, R.; Croese, J.; Bethony, J. Hookworm
665 Infection. *Nat. Rev. Dis Prim.* **2016**, *2* (1), 16088.
- 666 (18) Zonta, M.; Oyhenart, E.; Navone, G. Nutritional Status, Body
667 Composition, and Intestinal Parasitism among the Mbyá-Guaraní⁶⁶⁸
669 Communities of Misiones, Argentina. *Am. J. Hum Biol.* **2009**, *22* (2),
670 193–200.
- 671 (19) Daub, J.; Loukas, A.; Pritchard, D.; Blaxter, M. A Survey of
672 Genes Expressed in Adults of the Human Hookworm, *Necator
673 Americanus. Parasitology* **2000**, *120* (2), 171–184.
- 674 (20) Rey-Burusco, M.; Ibáñez-Shimabukuro, M.; Gabrielsen, M.;
675 Franchini, G.; Roe, A.; Griffiths, K.; Zhan, B.; Cooper, A.; Kennedy,
676 M. W.; Córscico, B.; Smith, B. O. Diversity in the Structures and
677 Ligand-Binding Sites of Nematode Fatty Acid and Retinol-Binding
678 Proteins Revealed by Na-FAR-1 from *Necator Americanus. Biochem.*
679 **J.** **2015**, *471*, 403–414.
- 680 (21) Jordanova, R.; Groves, M.; Kostova, E.; Woltersdorf, C.;
681 Liebau, E.; Tucker, P. Fatty Acid- and Retinoid-Binding Proteins
682 Have Distinct Binding Pockets for the Two Types of Cargo. *J. Biol.
683 Chem.* **2009**, *284* (51), 35818–35826.
- 684 (22) Storch, J.; McDermott, L. Structural and Functional Analysis of
685 Fatty Acid-Binding Proteins. *J. Lipid Res.* **2009**, *50* (Suppl), S126–
686 S131.
- 687 (23) Storch, J.; Corsico, B. The Emerging Functions and
688 Mechanisms of Mammalian Fatty Acid-Binding Proteins. *Annu. Rev.
689 Nutr.* **2008**, *28*, 73–95.
- 690 (24) Banaszak, L.; Winter, N.; Xu, Z.; Bernlohr, D.; Cowan, S.;
691 Jones, T. Lipid-Binding Proteins: A Family of Fatty Acid and Retinoid
692 Transport Proteins. *Adv. Protein Chem.* **1994**, *45*, 89–151.
- 693 (25) Stewart, J. The Cytoplasmic Fatty-Acid-Binding Proteins:
694 Thirty Years and Counting. *Cell. Mol. Life Sci.* **2000**, *57*, 1345–1359.
- 695 (26) Friedman, R.; Nachliel, E.; Gutman, M. Fatty Acid Binding
696 Proteins: Same Structure but Different Binding Mechanisms?
697 Molecular Dynamics Simulations of Intestinal Fatty Acid Binding
698 Protein. *Biophys. J.* **2006**, *90* (March), 1535–1545.
- 699 (27) Hotamisligil, G.; Bernlohr, D. Metabolic Functions of FABPs:
700 Mechanisms and Therapeutic Implications. *Nat. Rev. Endocrinol.*
701 **2015**, *11* (10), 592–605.
- 702 (28) McDermott, L.; Cooper, A.; Kennedy, M. Novel Classes of
703 Fatty Acid and Retinol Binding Protein from Nematodes. *Mol. Cell.
704 Biochem.* **1999**, *192*, 69–75.
- 705 (29) Zimmerman, A. W.; Veerkamp, J. H. New Insights into the
706 Structure and Function of Fatty Acid-Binding Proteins. *Cell. Mol. Life
707 Sci.* **2002**, *59*, 1096–1116.
- 708 (30) Veerkamp, J.; Peeters, R.; RGHJ, M. Structural and Functional
709 Features of Different Types of Cytoplasmic Fatty Acid-Binding.
710 *Biochim. Biophys. Acta, Lipids Lipid Metab.* **1991**, *1081*, 1–24.
- 711 (31) Sha, R.; Kane, C.; Xu, Z.; Banaszak, L.; Bernlohr, D. Modulation
712 of Ligand Binding Affinity of the Adipocyte Lipid-Binding
713 Protein by Selective Mutation: Analysis in Vitro and in Situ. *J.
714 Biol. Chem.* **1993**, *268*, 7885–7892.
- 715 (32) Prinsen, C.; Veerkamp, J. Fatty Acid Binding and Conformational
716 Stability of Mutants of Human Muscle Fatty Acid-Binding
717 Protein. *Biochem. J.* **1996**, *314*, 253–260.
- 718 (33) Jakoby, M.; Miller, K.; Toner, J.; Bauman, A.; Cheng, L.; Li, E.;
719 et al. Ligand-Protein Electrostatic Interactions Govern the Specificity
720

- 720 of Retinol- and Fatty Acid-Binding Proteins. *Biochemistry* **1993**, *32*,
721 872–878.
- 722 (34) Thumser, A.; Evans, C.; Worrall, A.; Wilton, D. Effect on
723 Ligand Binding of Arginine Mutations in Recombinant Rat Liver
724 Fatty Acid-Binding Protein. *Biochem. J.* **1994**, *297*, 103–107.
- 725 (35) Thumser, A.; Voysey, J.; Wilton, D. Mutations of Recombinant
726 Rat Liver Fatty Acid-Binding Protein at Residues 102 and 122 Alter
727 Its Structural Integrity and Affinity for Physiological Ligands. *Biochem.*
728 *J.* **1996**, *314*, 943–949.
- 729 (36) Laukumaa, S.; Nieminen, T.; Raasakka, A.; Krokengen, O.;
730 Safaryan, A.; Hallin, E.; Brysbaert, G.; Lensink, M.; Ruskamo, S.;
731 Vattulainen, I.; Kursula, P. Structure and Dynamics of a Human
732 Myelin Protein P2 Portal Region Mutant Indicate Opening of the β
733 Barrel in Fatty Acid Binding Proteins. *BMC Struct. Biol.* **2018**, *18* (8),
734 1–13.
- 735 (37) Hodsdon, M. E.; Cistola, D. P. Discrete Backbone Disorder in
736 the Nuclear Magnetic Resonance Structure of Apo Intestinal Fatty
737 Acid-Binding Protein: Implications for the Mechanism of Ligand
738 Entry. *Biochemistry* **1997**, *36*, 1450–1460.
- 739 (38) Friedman, R.; Nachliel, E.; Gutman, M. Molecular Dynamics
740 Simulations of the Adipocyte Lipid Binding Protein Reveal a Novel
741 Entry Site for the Ligand. *Biochemistry* **2005**, *44*, 4275–4283.
- 742 (39) Tsafadia, Y.; Friedman, R.; Kadmon, J.; Selzer, A.; Nachliel, E.;
743 Gutman, M. Molecular Dynamics Simulations of Palmitate Entry into
744 the Hydrophobic Pocket of the Fatty Acid Binding Protein. *FEBS Lett.*
745 **2007**, *581* (6), 1243–1247.
- 746 (40) Matsuoka, D.; Sugiyama, S.; Murata, M.; Matsuoka, S. Molecular Dynamics Simulations of Heart-Type Fatty Acid Binding
747 Protein in Apo and Holo Forms, and Hydration Structure Analyses in
748 the Binding Cavity. *J. Phys. Chem. B* **2015**, *119* (1), 114–127.
- 750 (41) Laukumaa, S.; Nieminen, T.; Lehtimäki, M.; Aggarwal, S.;
751 Simons, M.; Koza, M. M.; Vattulainen, I.; Kursula, P.; Natali, F. F.
752 Dynamics of the Peripheral Membrane Protein P2 from Human
753 Myelin Measured by Neutron Scattering—A Comparison between
754 Wild-Type Protein and a Hinge Mutant. *PLoS One* **2015**, *10* (6),
755 e0128954.
- 756 (42) Guo, Y.; Duan, M.; Yang, M. The Observation of Ligand-Binding-Relevant Open States of Fatty Acid Binding Protein by
757 Molecular Dynamics Simulations and a Markov State Model. *Int. J. Mol. Sci.* **2019**, *20* (14), 3476.
- 758 (43) Andrew McCammon, J.; Harvey, S. C. *Dynamics of Proteins and Nucleic Acids*; Cambridge University Press: Cambridge, U.K., 1987.
- 759 (44) Karplus, M.; Kuriyan, J. Molecular Dynamics and Protein Function. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, *102*, 6679–6685.
- 760 (45) Karplus, M.; McCammon, J. A. Molecular Dynamics Simulations of Biomolecules. *Nat. Struct. Biol.* **2002**, *9*, 646–652.
- 761 (46) Brooks, C., III; Karplus, M.; Pettitt, B. M. *Proteins: A Theoretical Perspective of Dynamics, Structure, and Thermodynamics*; Prigogine, I., Rice, S. A., Eds.; John Wiley & Sons Ltd.: New York, 1987.
- 762 (47) Ichiye, T.; Karplus, M. Collective Motions in Proteins: A Covariance Analysis of Atomic Fluctuations in Molecular Dynamics and Normal Mode Simulations. *Proteins: Struct., Funct., Genet.* **1991**, *11*, 205–217.
- 763 (48) Horiuchi, T.; Go, N. Projection of Monte Carlo and Molecular Dynamics Trajectories onto the Normal Mode Axes: Human Lysozyme. *Proteins: Struct., Funct., Genet.* **1991**, *10* (2), 106–116.
- 764 (49) van Aalten, D. M. F.; de Groot, B. L.; Findlay, J. B. C.; Berendsen, H. J. C.; Amadei, A. A Comparison of Techniques for Calculating Protein Essential Dynamics. *J. Comput. Chem.* **1997**, *18* (2), 169–181.
- 765 (50) Jolliffe, I. T. *Principal Component Analysis*, 2nd ed.; Springer-Verlag: Berlin, 2002.
- 766 (51) David, C. C.; Jacobs, D. J. *Protein Dynamics*; Livesay, D. R., Ed.; Methods in Molecular Biology; Humana Press: Totowa, NJ, 2014; Vol. 1084.
- 767 (52) Desdouits, N.; Nilges, M.; Blondel, A. Principal Component Analysis Reveals Correlation of Cavities Evolution and Functional Motions in Proteins. *J. Mol. Graphics Modell.* **2015**, *55*, 13–24.
- 768 (53) Barletta, G. P.; Fernandez-Alberti, S. Protein Fluctuations and Cavity Changes Relationship. *J. Chem. Theory Comput.* **2018**, *14* (2), 790 998–1008.
- 769 (54) *Lipid Binding Proteins within Molecular and Cellular Biochemistry*; Banaszak, L., Bernlohr, D. A., Eds.; Springer Science +Business Media, B.V.: Berlin.
- 770 (55) Hunter, N. H.; Bakula, B. C.; Bruce, C. D. Molecular Dynamics Simulations of Apo and Holo Forms of Fatty Acid Binding Protein 5 and Cellular Retinoic Acid Binding Protein II Reveal Highly Mobile Protein, Retinoic Acid Ligand, and Water Molecules. *J. Biomol. Struct. Dyn.* **2018**, *36* (7), 1893–1907.
- 771 (56) Rich, M.; Evans, J. S. Molecular Dynamics Simulations of Adipocyte Lipid-Binding Protein: Effect of Electrostatics and Acyl Chain Unsaturation. *Biochemistry* **1996**, *35* (5), 1506–1515.
- 772 (57) Long, D.; Mu, Y.; Yang, D. Molecular Dynamics Simulation of Ligand Dissociation from Liver Fatty Acid Binding Protein. *PLoS One* **2009**, *4* (6), e6081.
- 773 (58) Sivanesan, D.; Rajnarayanan, R.; Doherty, J.; Patabiraman, N. In-Silico Screening Using Flexible Ligand Binding Pockets: A Molecular Dynamics-Based Approach. *J. Comput.-Aided Mol. Des.* **2005**, *19* (4), 213–228.
- 774 (59) Salomon-Ferrer, R.; Case, D.; Walker, R. An Overview of the Amber Biomolecular Simulation Package. *WIREs Comput. Mol. Sci.* **2013**, *3*, 198–210.
- 775 (60) Case, D.; Cheatham, T. I.; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. J.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. The Amber Biomolecular Simulation Programs. *J. Comput. Chem.* **2005**, *26*, 1668–1688.
- 776 (61) Berman, H.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. The Protein Data Bank. *Nucleic Acids Res.* **2000**, *28*, 235–242.
- 777 (62) Sacchettini, J.; Gordon, J.; Banaszak, L. Refined Apoprotein Structure of Rat Intestinal Fatty Acid Binding Protein Produced in Escherichia Coli. *Proc. Natl. Acad. Sci. U. S. A.* **1989**, *86* (20), 7736–7740.
- 778 (63) Sacchettini, J.; Gordon, J.; Banaszak, L. Crystal Structure of Rat Intestinal Protein Refinement and Analysis of the Escherichia Coli-Derived Protein with Bound Palmitate. *J. Mol. Biol.* **1989**, *208*, 327–339.
- 779 (64) Hodsdon, M.; Ponder, J.; Cistola, D. The NMR Solution Structure of Intestinal Fatty Acid-Binding Protein Complexed with Palmitate: Application of a Novel Distance Geometry Algorithm. *J. Mol. Biol.* **1996**, *264*, 585–602.
- 780 (65) Ponder, J.; Case, D. Force Fields for Protein Simulations. *Adv. Protein Chem.* **2003**, *66*, 27–85.
- 781 (66) Maier, J.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K.; Simmerling, C. Ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from Ff99SB. *J. Chem. Theory Comput.* **2015**, *11*, 3696–3713.
- 782 (67) Jorgensen, W.; Chandrasekhar, J.; Madura, J.; Impey, R.; Klein, M. Comparison of Simple Potential Functions for Simulating Liquid Water. *J. Chem. Phys.* **1983**, *79*, 926–935.
- 783 (68) Amadei, A.; Linssen, A. B. M.; Berendsen, H. J. C. Essential Dynamics of Proteins. *Proteins: Struct., Funct., Genet.* **1993**, *17* (4), 412–425.
- 784 (69) Brooks, B.; Janezic, D.; Karplus, M. Harmonic Analysis of Large Systems. I. Methodology. *J. Comput. Chem.* **1995**, *16* (12), 1522–1542.
- 785 (70) Monzon, A. M.; Zea, D. J.; Fornasari, M. S.; Saldaño, T. E.; Fernandez-Alberti, S.; Tosatto, S. C. E.; Parisi, G. Conformational Diversity Analysis Reveals Three Functional Mechanisms in Proteins. *PLoS Comput. Biol.* **2017**, *13* (2), e1005398.
- 786 (71) Chen, Z.; Qiao, Y.; Klimtchuk, E.; Hamilton, J. A.; Cai, J.; Lu, C. Solution Structure and Backbone Dynamics of Human Liver Fatty Acid Binding Protein: Fatty Acid Binding Revisited. *Biophys. J.* **2012**, *102* (11), 2585–2594.
- 787 (72) Hodsdon, M. E.; Cistola, D. P. Ligand Binding Alters Backbone Mobility of Intestinal Fatty Acid-Binding Protein as Monitored by ¹⁵N NMR Relaxation and ¹H Exchange. *Biochemistry* **1997**, *36* (8), 2278–2290.

- 858 (73) Arighi, C.; Rossi, J.; Delfino, J. Temperature-Induced
859 Conformational Switch in Intestinal Fatty Acid Binding Protein
860 (IFABP) Revealing an Alternative Mode for Ligand Binding.
861 *Biochemistry* **2003**, *42* (24), 7539–7551.
- 862 (74) Curto, L.; Caramelo, J.; Delfino, J. Delta98delta, a Functional
863 All-Beta-Sheet Abridged Form of Intestinal Fatty Acid Binding
864 Protein.Delta98delta, a Functional All-Beta-Sheet Abridged Form of
865 Intestinal Fatty A. *Biochemistry* **2005**, *44* (42), 13847–13857.
- 866 (75) Porfido, J.; Alvite, G.; Silva, V.; Kennedy, M.; Esteves, A.;
867 Corsico, B. Direct Interaction between EgFABP1, a Fatty Acid
868 Binding Protein from *Echinococcus Granulosus*, and Phospholipid
869 Membranes. *PLoS Neglected Trop. Dis.* **2012**, *6* (11), e1893.
- 870 (76) Garofalo, A.; Kennedy, M.; Bradley, J. The FAR Proteins of
871 Parasitic Nematodes: Their Possible Involvement in the Pathogenesis
872 of Infection and the Use of *Caenorhabditis Elegans* as a Model
873 System to Evaluate Their Function. *Med. Microbiol. Immunol.* **2003**,
874 *192*, 47–52.
- 875 (77) Kennedy, M. The Nematode Polyprotein Allergens/Antigens.
876 *Parasitol. Today* **2000**, *16*, 373–380.
- 877 (78) Kennedy, M.; Scott, J.; Lo, S.; Beauchamp, J.; McManus, D. Sj-
878 FABPcfatty- Acid-Binding Protein of the Human Blood Fluke
879 *Schistosoma Japonicum*: Structural and Functional Characterization
880 and Unusual Solvent Exposure of a Portal-Proximal Tryptophan
881 Residue. *Biochem. J.* **2000**, *349*, 377–384.